Neuro Pace Inc NPCE
Institutional shares held
24.7 Million
20.2K
calls
21.9K
puts
Total value of holdings
$317M
$259K
calls
$281K
puts
Market Cap
$319M
24,846,900
Shares Out.
Institutional ownership
99.45%
# of Institutions
85
We take great care to ensure that the data presented and summarized in this overview for NeuroPace Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NPCE
View all-
Polar Capital Holdings PLC London, X03.1MShares$39.8 Million0.17% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.96MShares$38 Million1.88% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.61MShares$33.6 Million0.93% of portfolio
-
Morgan Stanley New York, NY2.55MShares$32.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.44MShares$18.4 Million0.0% of portfolio
-
First Light Asset Management, LLC Edina, MN1.36MShares$17.5 Million1.71% of portfolio
-
Armistice Capital, LLC New York, NY1.3MShares$16.7 Million0.21% of portfolio
-
Kent Lake Capital LLC Mill Valley, CA1.14MShares$14.7 Million3.99% of portfolio
-
Kent Lake Pr LLC Anasco, PR1MShares$12.8 Million5.21% of portfolio
-
Driehaus Capital Management LLC Chicago, IL940KShares$12.1 Million0.08% of portfolio
Latest Institutional Activity in NPCE
Top Purchases
Top Sells
About NPCE
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Insider Transactions at NPCE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 03
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,338
-1.67%
|
$21,408
$16.66 P/Share
|
|
Nov 27
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
357
-0.44%
|
$5,712
$16.5 P/Share
|
|
Nov 27
2025
|
Joel Becker CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,126
-1.08%
|
$18,016
$16.5 P/Share
|
|
Nov 20
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,051
-3.65%
|
$39,663
$13.5 P/Share
|
|
Sep 19
2025
|
Frank M Fischer |
BUY
Grant, award, or other acquisition
|
Direct |
2,389
+0.4%
|
$21,501
$9.94 P/Share
|
|
Sep 19
2025
|
Rakhi Kumar |
BUY
Grant, award, or other acquisition
|
Direct |
1,509
+8.11%
|
$13,581
$9.94 P/Share
|
|
Sep 19
2025
|
Joseph Lacob |
BUY
Grant, award, or other acquisition
|
Direct |
1,131
+7.89%
|
$10,179
$9.94 P/Share
|
|
Sep 19
2025
|
Uri Geiger |
BUY
Grant, award, or other acquisition
|
Direct |
1,194
+8.28%
|
$10,746
$9.94 P/Share
|
|
Sep 03
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,337
-1.58%
|
$12,033
$9.36 P/Share
|
|
Aug 27
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
357
-0.42%
|
$2,856
$8.88 P/Share
|
|
Aug 27
2025
|
Joel Becker CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,126
-1.07%
|
$9,008
$8.88 P/Share
|
|
Aug 20
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,052
-3.46%
|
$24,416
$8.66 P/Share
|
|
Jun 21
2025
|
Frank M Fischer |
BUY
Grant, award, or other acquisition
|
Direct |
2,281
+0.39%
|
$22,810
$10.41 P/Share
|
|
Jun 21
2025
|
Joseph Lacob |
BUY
Grant, award, or other acquisition
|
Direct |
1,080
+8.21%
|
$10,800
$10.41 P/Share
|
|
Jun 21
2025
|
Rakhi Kumar |
BUY
Grant, award, or other acquisition
|
Direct |
1,440
+8.45%
|
$14,400
$10.41 P/Share
|
|
Jun 21
2025
|
Uri Geiger |
BUY
Grant, award, or other acquisition
|
Direct |
1,140
+8.65%
|
$11,400
$10.41 P/Share
|
|
Jun 20
2025
|
Patrick F. Williams Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,850
+50.0%
|
-
|
|
Jun 03
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,338
-1.53%
|
$17,394
$13.54 P/Share
|
|
Jun 03
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,337
-1.01%
|
$17,381
$13.54 P/Share
|
|
May 27
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
357
-0.41%
|
$4,284
$12.66 P/Share
|
Last 12 Months Summary
Buy / Acquisition
156K
Shares
From
8
Insiders
| Grant, award, or other acquisition | 156K shares |
|---|
Sell / Disposition
5.56M
Shares
From
6
Insiders
| Open market or private sale | 5.52M shares |
|---|---|
| Payment of exercise price or tax liability | 40.2K shares |